Overview

Efficacy and Safety of CD5024 1% in Acne Vulgaris

Status:
Completed
Trial end date:
2016-11-02
Target enrollment:
Participant gender:
Summary
Exploratory, multi-center, randomised, investigator-blinded, vehicle controlled study using intra-individual comparison involving subjects with acne vulgaris on face to evaluate the efficacy of CD5024 1% cream over a 6-week treatment period compared to its vehicle.
Phase:
Phase 2
Details
Lead Sponsor:
Galderma R&D